Melatonin Use in Infants Admitted to Intensive Care Units
OBJECTIVES Sleep deprivation is a risk factor for delirium development, which is a frequent complication of intensive care unit admission. Melatonin has been used for both delirium prevention and treatment. Melatonin safety, efficacy, and dosing information in neonates and infants is lacking. The pu...
Saved in:
Published in | The journal of pediatric pharmacology and therapeutics Vol. 28; no. 7; pp. 635 - 642 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
2023
|
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVES
Sleep deprivation is a risk factor for delirium development, which is a frequent complication of intensive care unit admission. Melatonin has been used for both delirium prevention and treatment. Melatonin safety, efficacy, and dosing information in neonates and infants is lacking. The purpose of this study was to describe melatonin use in infants regarding indication, dosing, efficacy, and safety.
METHODS
This descriptive, retrospective study included infants <12 months of age admitted to an intensive care unit receiving melatonin. Data collection included demographics, melatonin regimen, sedative and analgesic agents, antipsychotics, and delirium-causing medications. The primary objective was to identify the melatonin indication and median dose. The secondary objectives included change in delirium, pain, and sedation scores; change in dosing of analgesic and sedative agents; and adverse event identification. Wilcoxon signed rank tests and linear mixed models were employed with significance defined at p < 0.05.
RESULTS
Fifty-five patients were included, with a median age of 5.5 months (IQR, 3.9–8.2). Most (n = 29; 52.7%) received melatonin for sleep promotion. The median body weight–based dose was 0.31 mg/kg/dose (IQR, 0.20–0.45). There was a statistical reduction in cumulative morphine equivalent dosing 72 hours after melatonin administration versus before, 17.1 versus 21.4 mg/kg (p = 0.049). No adverse events were noted.
CONCLUSIONS
Most patients (n = 29; 52.7%) received melatonin for sleep promotion at a median dose was 0.31 mg/kg/dose. Initiation of melatonin was associated with a reduction of opioid exposure; however, there was no reduction in pain/sedation scores. |
---|---|
AbstractList | OBJECTIVESSleep deprivation is a risk factor for delirium development, which is a frequent complication of intensive care unit admission. Melatonin has been used for both delirium prevention and treatment. Melatonin safety, efficacy, and dosing information in neonates and infants is lacking. The purpose of this study was to describe melatonin use in infants regarding indication, dosing, efficacy, and safety.METHODSThis descriptive, retrospective study included infants <12 months of age admitted to an intensive care unit receiving melatonin. Data collection included demographics, melatonin regimen, sedative and analgesic agents, antipsychotics, and delirium-causing medications. The primary objective was to identify the melatonin indication and median dose. The secondary objectives included change in delirium, pain, and sedation scores; change in dosing of analgesic and sedative agents; and adverse event identification. Wilcoxon signed rank tests and linear mixed models were employed with significance defined at p < 0.05.RESULTSFifty-five patients were included, with a median age of 5.5 months (IQR, 3.9-8.2). Most (n = 29; 52.7%) received melatonin for sleep promotion. The median body weight-based dose was 0.31 mg/kg/dose (IQR, 0.20-0.45). There was a statistical reduction in cumulative morphine equivalent dosing 72 hours after melatonin administration versus before, 17.1 versus 21.4 mg/kg (p = 0.049). No adverse events were noted.CONCLUSIONSMost patients (n = 29; 52.7%) received melatonin for sleep promotion at a median dose was 0.31 mg/kg/dose. Initiation of melatonin was associated with a reduction of opioid exposure; however, there was no reduction in pain/sedation scores. OBJECTIVES Sleep deprivation is a risk factor for delirium development, which is a frequent complication of intensive care unit admission. Melatonin has been used for both delirium prevention and treatment. Melatonin safety, efficacy, and dosing information in neonates and infants is lacking. The purpose of this study was to describe melatonin use in infants regarding indication, dosing, efficacy, and safety. METHODS This descriptive, retrospective study included infants <12 months of age admitted to an intensive care unit receiving melatonin. Data collection included demographics, melatonin regimen, sedative and analgesic agents, antipsychotics, and delirium-causing medications. The primary objective was to identify the melatonin indication and median dose. The secondary objectives included change in delirium, pain, and sedation scores; change in dosing of analgesic and sedative agents; and adverse event identification. Wilcoxon signed rank tests and linear mixed models were employed with significance defined at p < 0.05. RESULTS Fifty-five patients were included, with a median age of 5.5 months (IQR, 3.9–8.2). Most (n = 29; 52.7%) received melatonin for sleep promotion. The median body weight–based dose was 0.31 mg/kg/dose (IQR, 0.20–0.45). There was a statistical reduction in cumulative morphine equivalent dosing 72 hours after melatonin administration versus before, 17.1 versus 21.4 mg/kg (p = 0.049). No adverse events were noted. CONCLUSIONS Most patients (n = 29; 52.7%) received melatonin for sleep promotion at a median dose was 0.31 mg/kg/dose. Initiation of melatonin was associated with a reduction of opioid exposure; however, there was no reduction in pain/sedation scores. |
Author | Johnson, Peter N. Bradford, Caitlyn Chaaban, Hala Harkin, Maura Miller, Jamie L. Neely, Stephen B. |
Author_xml | – sequence: 1 givenname: Caitlyn surname: Bradford fullname: Bradford, Caitlyn – sequence: 2 givenname: Jamie L. surname: Miller fullname: Miller, Jamie L. – sequence: 3 givenname: Maura surname: Harkin fullname: Harkin, Maura – sequence: 4 givenname: Hala surname: Chaaban fullname: Chaaban, Hala – sequence: 5 givenname: Stephen B. surname: Neely fullname: Neely, Stephen B. – sequence: 6 givenname: Peter N. surname: Johnson fullname: Johnson, Peter N. |
BookMark | eNo9kE1LxDAQhoOsYF33D3jq0UvXfKc5LkXdhRUvFryFNJ1CpU3XJiv4701ZcS4vDM87DM8tWvnJA0L3BG9FKdkjEYIUUilZ0HKrtpKJK5RRxkjBePmxQtk_cIM2IXziNJwrLHiG9CsMNk6-93kdIE9x8J31MeS7duxjhDaPU9pF8KH_hryyM-S172O4Q9edHQJs_nKN6uen92pfHN9eDtXuWDiisShK6SgQ2knNXEetY1wqphve6FYAJw5YS6x0lmnepL8aToRrKHFcd6WynLA1erjcPc3T1xlCNGMfHAyD9TCdg6GlFlJrLXFC6QV18xTCDJ05zf1o5x9DsFlUmcWEWUykmlEmqWK__zNcAg |
Cites_doi | 10.1016/j.ejpn.2014.12.007 10.15585/mmwr.mm7122a1 10.1001/jamapediatrics.2019.2084 10.1176/appi.ajp.2010.09111606 10.1002/phar.2408 10.3390/ijms22041671 10.1542/hpeds.2021-006117 10.1007/s00213-010-1962-0 10.1177/0885066615592348 10.1007/s00134-021-06490-3 10.1212/WNL.0000000000009033 10.1097/PCC.0000000000002873 10.1097/CCM.0b013e3182a66b76 10.1891/0730-0832/11-T-727 10.1136/fn.85.1.F36 10.1210/jcem.86.10.7901 10.5664/jcsm.6462 |
ContentType | Journal Article |
DBID | AAYXX CITATION 7X8 |
DOI | 10.5863/1551-6776-28.7.635 |
DatabaseName | CrossRef MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2331-348X |
EndPage | 642 |
ExternalDocumentID | 10_5863_1551_6776_28_7_635 |
GroupedDBID | 5GY AAKDD AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL CITATION DIK E3Z OK1 RPM Y3D 7X8 |
ID | FETCH-LOGICAL-c1905-86c2e12f693cf2ac346739b4b9d5e41ce3d1a6ca394b000b415cb21c49f87a413 |
ISSN | 1551-6776 |
IngestDate | Fri Aug 16 12:15:21 EDT 2024 Fri Aug 23 01:00:45 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1905-86c2e12f693cf2ac346739b4b9d5e41ce3d1a6ca394b000b415cb21c49f87a413 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://meridian.allenpress.com/jppt/article-pdf/28/7/635/3293048/i2331-348x-28-7-635.pdf |
PQID | 2895699960 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_2895699960 crossref_primary_10_5863_1551_6776_28_7_635 |
PublicationCentury | 2000 |
PublicationDate | 2023-00-00 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – year: 2023 text: 2023-00-00 |
PublicationDecade | 2020 |
PublicationTitle | The journal of pediatric pharmacology and therapeutics |
PublicationYear | 2023 |
References | Procaccini (2023112808583322100_i2331-348X-28-7-635-b1) 2020; 40 Traube (2023112808583322100_i2331-348X-28-7-635-b8) 2014; 42 Lelak (2023112808583322100_i2331-348X-28-7-635-b16) 2022; 71 Burry (2023112808583322100_i2331-348X-28-7-635-b7) 2021; 47 Zhdanova (2023112808583322100_i2331-348X-28-7-635-b17) 2001; 86 Mo (2023112808583322100_i2331-348X-28-7-635-b4) 2016; 31 Debillon (2023112808583322100_i2331-348X-28-7-635-b11) 2001; 85 Bruni (2023112808583322100_i2331-348X-28-7-635-b13) 2015; 19 Procaccini (2023112808583322100_i2331-348X-28-7-635-b3) 2021; 11 Littell (2023112808583322100_i2331-348X-28-7-635-b12) 2006 Buckley (2023112808583322100_i2331-348X-28-7-635-b18) 2020; 94 Koopman-Verhoeff (2023112808583322100_i2331-348X-28-7-635-b2) 2019; 173 Liviskie (2023112808583322100_i2331-348X-28-7-635-b15) 2021; 40 Laudone (2023112808583322100_i2331-348X-28-7-635-b6) 2021; 26 Silver (2023112808583322100_i2331-348X-28-7-635-b10) 2010; 167 Yates (2023112808583322100_i2331-348X-28-7-635-b19) 2021; 22 Smith (2023112808583322100_i2331-348X-28-7-635-b5) 2022; 23 Van Geijlswijk (2023112808583322100_i2331-348X-28-7-635-b14) 2010; 212 Johnson (2023112808583322100_i2331-348X-28-7-635-b9) 2020 Erland (2023112808583322100_i2331-348X-28-7-635-b20) 2017; 13 |
References_xml | – volume: 19 start-page: 122 issue: (2) year: 2015 ident: 2023112808583322100_i2331-348X-28-7-635-b13 article-title: Current role of melatonin in pediatric neurology: clinical recommendations publication-title: Eur J Paediatr Neurol doi: 10.1016/j.ejpn.2014.12.007 contributor: fullname: Bruni – volume-title: SAS for Mixed Models year: 2006 ident: 2023112808583322100_i2331-348X-28-7-635-b12 contributor: fullname: Littell – volume: 71 start-page: 725 issue: (22) year: 2022 ident: 2023112808583322100_i2331-348X-28-7-635-b16 article-title: Pediatric melatonin ingestions–United States 2012-2021 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7122a1 contributor: fullname: Lelak – volume: 173 start-page: 883 issue: (9) year: 2019 ident: 2023112808583322100_i2331-348X-28-7-635-b2 article-title: Association of sleep problems and melatonin use in school-aged children publication-title: JAMA Pediatr doi: 10.1001/jamapediatrics.2019.2084 contributor: fullname: Koopman-Verhoeff – volume: 167 start-page: 1172 issue: (10) year: 2010 ident: 2023112808583322100_i2331-348X-28-7-635-b10 article-title: Infant delirium in pediatric critical care settings publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2010.09111606 contributor: fullname: Silver – volume: 40 start-page: 692 issue: (7) year: 2020 ident: 2023112808583322100_i2331-348X-28-7-635-b1 article-title: Melatonin use in hospitalized children for non-anesthetic indications: a systemic review publication-title: Pharmacotherapy doi: 10.1002/phar.2408 contributor: fullname: Procaccini – volume: 22 start-page: 1671 issue: (4) year: 2021 ident: 2023112808583322100_i2331-348X-28-7-635-b19 article-title: Preventing brain injury in the preterm infant–current controversies and potential therapies publication-title: Int J Mol Sci doi: 10.3390/ijms22041671 contributor: fullname: Yates – volume: 11 start-page: e308–311 year: 2021 ident: 2023112808583322100_i2331-348X-28-7-635-b3 article-title: Melatonin administration patterns for pediatric inpatients in a tertiary children’s hospital publication-title: Hosp Pediatr doi: 10.1542/hpeds.2021-006117 contributor: fullname: Procaccini – volume: 212 start-page: 379 issue: (3) year: 2010 ident: 2023112808583322100_i2331-348X-28-7-635-b14 article-title: Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-010-1962-0 contributor: fullname: Van Geijlswijk – volume: 31 start-page: 451 issue: (7) year: 2016 ident: 2023112808583322100_i2331-348X-28-7-635-b4 article-title: Emerging role of melatonin and melatonin receptor agonists in sleep and delirium in intensive care unit patients publication-title: J Intensive Care Med doi: 10.1177/0885066615592348 contributor: fullname: Mo – volume: 47 start-page: 943 issue: (9) year: 2021 ident: 2023112808583322100_i2331-348X-28-7-635-b7 article-title: Pharmacological and non-pharmacological interventions to prevent delirium in critically ill patients: a systematic review and network meta-analysis publication-title: Intensive Care Med doi: 10.1007/s00134-021-06490-3 contributor: fullname: Burry – volume: 26 start-page: 361 issue: (4) year: 2021 ident: 2023112808583322100_i2331-348X-28-7-635-b6 article-title: Evaluation of melatonin practices for delirium in pediatric critically ill patients publication-title: J Pediatr Pharmacol Ther contributor: fullname: Laudone – start-page: 900 volume-title: Pediatric Pharmacotherapy year: 2020 ident: 2023112808583322100_i2331-348X-28-7-635-b9 contributor: fullname: Johnson – volume: 94 start-page: 392 issue: (9) year: 2020 ident: 2023112808583322100_i2331-348X-28-7-635-b18 article-title: Practice guideline: treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder publication-title: Neurology doi: 10.1212/WNL.0000000000009033 contributor: fullname: Buckley – volume: 23 start-page: e74 issue: (2) year: 2022 ident: 2023112808583322100_i2331-348X-28-7-635-b5 article-title: PANDEM guidelines for infants and children publication-title: Ped Crit Care Med doi: 10.1097/PCC.0000000000002873 contributor: fullname: Smith – volume: 42 start-page: 656 issue: (3) year: 2014 ident: 2023112808583322100_i2331-348X-28-7-635-b8 article-title: Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU publication-title: Crit Care Med doi: 10.1097/CCM.0b013e3182a66b76 contributor: fullname: Traube – volume: 40 start-page: 103 issue: (2) year: 2021 ident: 2023112808583322100_i2331-348X-28-7-635-b15 article-title: Delirium in the NICU: risk or reality? publication-title: Neonatal Netw doi: 10.1891/0730-0832/11-T-727 contributor: fullname: Liviskie – volume: 85 start-page: F36 issue: (1) year: 2001 ident: 2023112808583322100_i2331-348X-28-7-635-b11 article-title: Development and initial validation of the EDIN scale, a new tool for assessing prolonged pain in preterm infants publication-title: Arch Dis Child Fetal Neonatal doi: 10.1136/fn.85.1.F36 contributor: fullname: Debillon – volume: 86 start-page: 4727 issue: (10) year: 2001 ident: 2023112808583322100_i2331-348X-28-7-635-b17 article-title: Melatonin treatment for age-related insomnia publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.86.10.7901 contributor: fullname: Zhdanova – volume: 13 start-page: 275 issue: (2) year: 2017 ident: 2023112808583322100_i2331-348X-28-7-635-b20 article-title: Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content publication-title: J Clin Sleep Med doi: 10.5664/jcsm.6462 contributor: fullname: Erland |
SSID | ssj0000447054 |
Score | 2.2682204 |
Snippet | OBJECTIVES
Sleep deprivation is a risk factor for delirium development, which is a frequent complication of intensive care unit admission. Melatonin has been... OBJECTIVESSleep deprivation is a risk factor for delirium development, which is a frequent complication of intensive care unit admission. Melatonin has been... |
SourceID | proquest crossref |
SourceType | Aggregation Database |
StartPage | 635 |
Title | Melatonin Use in Infants Admitted to Intensive Care Units |
URI | https://search.proquest.com/docview/2895699960 |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxFMsLwWJW5VSO34kR7Tsqrtsl0sr9WbZjiOQIK3a9LD8emacOMkCh4VLWkWpI818mvlmOg9C3itboR8oUkWpS3kpytQIalNqwPvNrJPeY3Py4krOV_xiLdbDuqPQXdLYqfv5176S_9Eq3AO9YpfsP2i2PxRuwHfQL1xBw3C9lY4XWMmG-dTJah-Gf5zXVahrwZG4DXJJYJZDkTr2GgWSuR9TUgTKaH7ENu7umGyHqdbXsdAy9moNyfWdKWN9_Aku4bnu0Ta0GV6YH9_8ZEhzm123BGxhDruhVOirMbbNx87NdzPOR7TNwtF4CppK1e5zidaV5SMUqZGplO2Yks7rynbG1u8GXeQSB0v0J6csn6pp_9Px9OyrL_psdXmpl6fr5V1yj6lC4C6FT-ef-5zbjHM1C4vx-gPbPip8zYc_X3KTq9x01YF_LB-Rh13gkHxsUfCY3PH1E3J_0ZVGPCVFD4YEwJDARweGJIIhaTZJD4YEwZAEMDwjq7PT5ck87fZipA7om0hz6ZinrJJF5ipmXAbOLisst0UpPKfOZyU10pms4MjxLHA0Zxl1vKhyZYC1PCdH9ab2L0gCJwBHzagsS8mddTitjVXCMVZCaJDLYzKJEtDbdvyJhrAR5aVRXhrlpVmulQZ5HZN3UUgarBT-9WRqvzns4QmIwzG2nr28xTOvyAOGXSYh0_WaHDW7g38D3K-xb4NCfwGNgVfa |
link.rule.ids | 315,786,790,4043,27954,27955,27956 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Melatonin+Use+in+Infants+Admitted+to+Intensive+Care+Units&rft.jtitle=The+journal+of+pediatric+pharmacology+and+therapeutics&rft.au=Bradford%2C+Caitlyn&rft.au=Miller%2C+Jamie+L&rft.au=Harkin%2C+Maura&rft.au=Chaaban%2C+Hala&rft.date=2023&rft.issn=1551-6776&rft.volume=28&rft.issue=7&rft.spage=635&rft.epage=642&rft_id=info:doi/10.5863%2F1551-6776-28.7.635&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1551-6776&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1551-6776&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1551-6776&client=summon |